

Haematologica
HAEMATOL/2014/121459
Version 3

Ofatumumab monotherapy in fludarabine-refractory chronic
lymphocytic leukemia: final results from a pivotal study

Disclosures: Conflict-of-interest disclosure: R.C.J., I.V.G., J.L.P., N.G., H.S., N.L., and S.L. are employed by and have an ownership stake in Genmab or GlaxoSmithKline; A.O., J.M., S.S., T.R., and P.H. received research funding from Genmab or GlaxoSmithKline; A.O., S.S., P.H., T.K., and W.G.W. received honoraria from Genmab or GlaxoSmithKline; N.L. is a member of the board of directors of Genmab; S. P.-I., T.J.K., C.D.W., A.H., M.T., M.J.S.D., and M.P. declare no competing financial interests.

Contributions: Contribution: A.O., P.H., N.L., S.L., and W.G.W. conceived and designed the research; A.O., S.P.-I., T.J.K., J.M., S.S., C.D.W., A.H., R.R.F., T.R., P.H., M.T., M.J.S.D., M.P., T.K., and W.G.W. performed the research; A.O., R.C.J., T.J.K., S.S., C.D.W., R.R.F., T.R., M.T., M.J.S.D., I.V.G., J.L.P., N.G., H.S., N.L., W.G.W. analyzed and interpreted the results; A.O., R.C.J., T.J.K., S.S., C.D.W., A.H., R.R.F., T.R., P.H., I.V.G., J.L.P., N.G., H.S., N.L., S.L., and W.G.W. wrote and reviewed the manuscript; A.O., R.C.J., S. P.-I., T.J.K., J.M., S.S., C.D.W., A.H., R.R.F., T.R., P.H., M.T., M.J.S.D., M.P., T.K., I.V.G., J.L.P., N.G., H.S., N.L., S.L., and W.G.W. approved the manuscript.